

# Lisa A Carey

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/8324475/publications.pdf](https://exaly.com/author-pdf/8324475/publications.pdf)

Version: 2024-02-01

230  
papers

28,371  
citations

11078

71  
h-index

6192

160  
g-index

334  
all docs

334  
docs citations

334  
times ranked

34970  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2 <sup>+</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7. <i>Clinical Cancer Research</i> , 2024, 30, 793-802.	7.2	3
2	Cardiotoxicity of Agents Used in Patients With Breast Cancer. <i>JCO Oncology Practice</i> , 2024, 20, 38-46.	2.8	1
3	Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2024, 35, 159-182.	1.3	60
4	Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2024, 33, 654-661.	1.9	1
5	Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. <i>Journal of Clinical Oncology</i> , 2024, 42, 1738-1744.	15.4	10
6	Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network <sup>2</sup> Breast dataset (SCAN-B). <i>ESMO Open</i> , 2024, 9, 102388.	4.4	0
7	Global post-mortem tissue donation programmes to accelerate cancer research. <i>Nature Reviews Cancer</i> , 2024, 24, 289-290.	28.8	0
8	Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2024, 10, .	5.4	1
9	Differences in 21-Gene and PAM50 Recurrence Scores in Younger and Black Women With Breast Cancer. <i>JCO Precision Oncology</i> , 2024, , .	3.2	0
10	Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502. <i>Npj Breast Cancer</i> , 2024, 10, .	5.4	0
11	Real-world treatment patterns and outcomes in patients with HR+/HER2 <sup>+</sup> metastatic breast cancer treated with chemotherapy in the United States. <i>ESMO Open</i> , 2024, 9, 103691.	4.4	0
12	Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?. <i>ESMO Open</i> , 2024, 9, 103695.	4.4	0
13	Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial. <i>Clinical Cancer Research</i> , 2023, 29, 784-790.	7.2	7
14	Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor <sup>+</sup> Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. <i>Journal of Clinical Oncology</i> , 2023, 41, 1318-1320.	15.4	13
15	Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance). <i>Journal of Clinical Oncology</i> , 2023, 41, 3184-3193.	15.4	26
16	Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors. <i>Npj Breast Cancer</i> , 2023, 9, .	5.4	1
17	Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors. <i>Journal of Immunology</i> , 2023, 211, 219-228.	0.8	2
18	De Novo Oligometastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 5237-5241.	15.4	2

#	ARTICLE	IF	CITATIONS
19	Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. <i>Nature Communications</i> , 2023, 14, .	13.2	2
20	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. <i>JCO Oncology Practice</i> , 2022, 18, 211-216.	2.8	12
21	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267.	7.2	39
22	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1323-1334.	15.4	77
23	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. <i>Npj Breast Cancer</i> , 2022, 8, .	5.4	4
24	Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancerâ€”phase 3 ASCENT study subanalysis. <i>Npj Breast Cancer</i> , 2022, 8, .	5.4	32
25	Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptorâ€”Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3618-3629.	7.2	14
26	Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 153-162.	2.5	11
27	Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2â€”Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptorâ€”Negative: ASCO Guideline Rapid Recommendation Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 3088-3090.	15.4	18
28	Triple negative breast cancer: Pitfalls and progress. <i>Npj Breast Cancer</i> , 2022, 8, .	5.4	174
29	Obesity and Breast Cancer Metastasis across Genomic Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1944-1951.	1.9	4
30	A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	5.4	7
31	Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	5.4	35
32	Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors. <i>Npj Breast Cancer</i> , 2022, 8, .	5.4	39
33	Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa072.	2.8	16
34	Patientâ€”reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer. <i>Cancer</i> , 2021, 127, 957-967.	4.1	11
35	Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer. <i>Cancer</i> , 2021, 127, 922-930.	4.1	23
36	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1143-1155.	6.4	14

#	ARTICLE	IF	CITATIONS
37	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3116-3125.	7.2	10
38	Benchmarks for Academic Oncology Faculty. <i>JCO Oncology Practice</i> , 2021, 17, e440-e444.	2.8	1
39	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1529-1541.	30.1	740
40	Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021, 28, 5960-5971.	2.0	26
41	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab025.	2.8	10
42	Finding the positive in triple-negative breast cancer. <i>Nature Cancer</i> , 2021, 2, 476-478.	12.3	6
43	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 1485-1505.	15.4	472
44	FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. <i>Npj Breast Cancer</i> , 2021, 7, 51.	5.4	15
45	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4883-4897.	7.2	12
46	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	15.4	46
47	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021, 69, 103451.	6.0	10
48	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	15.4	29
49	A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer. <i>Future Oncology</i> , 2021, 17, 3911-3924.	2.4	9
50	Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer. <i>Future Oncology</i> , 2021, 17, 4665-4676.	2.4	11
51	Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 48-52.	1.6	0
52	Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 185-195.	2.5	12
53	Weight trajectories in women receiving systemic adjuvant therapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 709-720.	2.5	24
54	Borderline Estrogen Receptor–Positive Breast Cancers in Black and White Women. <i>Journal of the National Cancer Institute</i> , 2020, 112, 728-736.	6.4	20

#	ARTICLE	IF	CITATIONS
55	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	30.1	877
56	Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, <i>p16INK4a</i> . <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa082.	2.8	18
57	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4184-4193.	15.4	81
58	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	10.8	55
59	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	15.4	306
60	Integrating Biology and Access to Care in Addressing Breast Cancer Disparities: 25 Years' Research Experience in the Carolina Breast Cancer Study. <i>Current Breast Cancer Reports</i> , 2020, 12, 149-160.	1.1	5
61	Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. <i>Clinical Cancer Research</i> , 2020, 26, 4911-4920.	7.2	17
62	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. <i>Clinical Cancer Research</i> , 2020, 26, 2783-2788.	7.2	33
63	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	8.0	105
64	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1346-1366.	15.4	771
65	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 545-563.	2.5	222
66	Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. <i>Cancer</i> , 2020, 126, 3084-3093.	4.1	28
67	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 4871-4887.	8.2	56
68	Race and delays in breast cancer treatment across the care continuum in the Carolina Breast Cancer Study. <i>Cancer</i> , 2019, 125, 3985-3992.	4.1	46
69	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, <i>Research Directions</i> . <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	2.8	13
70	Toronto Workshop on Late Recurrence in Estrogen Receptor-positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	2.8	20
71	Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. <i>PLoS ONE</i> , 2019, 14, e0211488.	2.5	10
72	Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2189-2192.	15.4	12

#	ARTICLE	IF	CITATIONS
73	Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. <i>Cancer</i> , 2019, 125, 2945-2954.	4.1	63
74	Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310.	2.5	32
75	Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 321-328.	2.5	18
76	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.	15.4	38
77	Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. <i>Oncologist</i> , 2019, 24, 762-771.	4.1	62
78	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1868-1875.	15.4	237
79	Research priorities in prediction of response in early breast cancer. <i>Breast</i> , 2019, 48, S31-S33.	2.3	1
80	HITTING A MOVING TARGET: 2019 STANDARDS OF CARE AND TREATMENT OPTIMIZATION FOR HER2+ ABC. <i>Breast</i> , 2019, 48, S29-S30.	2.3	0
81	PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. <i>Cancer Prevention Research</i> , 2018, 11, 327-336.	1.6	7
82	Influence of provider factors and race on uptake of breast cancer gene expression profiling. <i>Cancer</i> , 2018, 124, 1743-1751.	4.1	9
83	Asparagine bioavailability governs metastasis in a model of breast cancer. <i>Nature</i> , 2018, 554, 378-381.	36.2	383
84	A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 289-297.	2.6	23
85	Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 235-248.	2.5	9
86	Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. <i>Journal of the National Cancer Institute</i> , 2018, 110, 176-182.	6.4	108
87	Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies. <i>Clinical Breast Cancer</i> , 2018, 18, 29-37.	2.6	35
88	Financial Impact of Breast Cancer in Black Versus White Women. <i>Journal of Clinical Oncology</i> , 2018, 36, 1695-1701.	15.4	94
89	A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance). <i>Annals of Oncology</i> , 2018, 29, vii50.	1.3	0
90	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 637-648.	2.5	43

#	ARTICLE	IF	CITATIONS
91	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5292-5304.	7.2	77
92	Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 111-120.	2.5	38
93	Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 1371-1383.	8.2	135
94	Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). <i>Journal of the American College of Surgeons</i> , 2017, 224, 688-694.	0.5	8
95	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. <i>Cancer Discovery</i> , 2017, 7, 302-321.	14.2	131
96	Weight changes in postmenopausal breast cancer survivors over 2Âyears of endocrine therapy: a retrospective chart review. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 375-388.	2.5	18
97	Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?. <i>Clinical Cancer Research</i> , 2017, 23, 2611-2616.	7.2	19
98	Evaluating the Effectiveness of Neoadjuvant Chemotherapy in Reducing Mastectomy for Women With Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2017, 1, p1x004.	2.8	3
99	De-escalating and escalating systemic therapy in triple negative breast cancer. <i>Breast</i> , 2017, 34, S112-S115.	2.3	13
100	Treating Triple Negative ABC. <i>Breast</i> , 2017, 36, S30-S31.	2.3	0
101	Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). <i>Breast Cancer Research and Treatment</i> , 2017, 165, 181-191.	2.5	57
102	Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3298-3305.	15.4	49
103	Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 3472-3483.	8.2	136
104	Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. <i>PLoS Medicine</i> , 2016, 13, e1002174.	8.4	89
105	I-SPY 2 â€” Toward More Rapid Progress in Breast Cancer Treatment. <i>New England Journal of Medicine</i> , 2016, 375, 83-84.	30.1	49
106	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <i>Npj Breast Cancer</i> , 2016, 2, .	5.4	82
107	Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. <i>Oncologist</i> , 2016, 21, 795-803.	4.1	44
108	Another Breast Cancer Entity Confirmed: Genomics of Invasive Lobular Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1838-1839.	15.4	5

#	ARTICLE	IF	CITATIONS
109	Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2003-2009.	15.4	67
110	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1557.	7.3	260
111	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 2602-2609.	15.4	108
112	Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study. <i>Breast Cancer Research</i> , 2016, 18, 79.	5.1	91
113	Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). <i>Breast Cancer Research and Treatment</i> , 2016, 159, 109-118.	2.5	47
114	Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States. <i>Journal of the American College of Surgeons</i> , 2016, 223, 717-728e4.	0.5	22
115	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2016, 160, 297-304.	2.5	67
116	Breast Cancer Screening in Low- and Middle-Income Countries: A Perspective From Malawi. <i>Journal of Global Oncology</i> , 2016, 2, 4-8.	1.7	37
117	Racial Variation in the Uptake of OncoDX Testing for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 130-138.	15.4	51
118	A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience. <i>Oncologist</i> , 2016, 21, 16-20.	4.1	34
119	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 29.	7.3	74
120	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 542-549.	15.4	343
121	CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials. <i>Clinical Cancer Research</i> , 2015, 21, 4027-4029.	7.2	5
122	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 134-141.	30.1	621
123	The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 874-882.	2.0	95
124	The Use of Bayesian Hierarchical Models for Adaptive Randomization in Biomarker-Driven Phase II Studies. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 66-88.	0.8	11
125	Palbociclib - Taking Breast-Cancer Cells Out of Gear. <i>New England Journal of Medicine</i> , 2015, 373, 273-274.	30.1	13
126	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 2361-2369.	15.4	202



#	ARTICLE	IF	CITATIONS
127	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	4.1	159
128	Chemotherapy-related amenorrhea after adjuvant paclitaxel+trastuzumab (APT trial). <i>Breast Cancer Research and Treatment</i> , 2015, 151, 589-596.	2.5	66
129	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1902-1909.	15.4	361
130	Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. <i>Cell Reports</i> , 2015, 11, 390-404.	6.3	259
131	Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 347-356.	2.5	39
132	Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 191-200.	2.5	16
133	Neoadjuvant clinical trial designs: Challenges of the genomic era. <i>Breast</i> , 2015, 24, S88-S90.	2.3	4
134	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 1098-1105.	7.2	35
135	TBCRC 008: Early Change in <sup>18</sup> F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2+Negative Primary Operable Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 31-37.	6.1	64
136	Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 13-21.	15.4	817
137	Making Sense of Dual HER2-Targeting in Early Breast Cancer?. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju259-dju259.	6.4	1
138	Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. <i>Science Signaling</i> , 2014, 7, ra29.	5.1	130
139	Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.4	184
140	Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju057.	6.4	228
141	How Low Should We Go? The Search for Balance in Management of Small Human Epidermal Growth Factor Receptor 2+Positive Breast Cancers. <i>Journal of Clinical Oncology</i> , 2014, 32, 2122-2124.	15.4	8
142	Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women. <i>Oncologist</i> , 2014, 19, 1076-1083.	4.1	129
143	Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3818-3829.	7.2	237
144	Defining success in neoadjuvant breast cancer trials. <i>Lancet</i> , The, 2014, 384, 115-116.	12.1	20

#	ARTICLE	IF	CITATIONS
145	Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. <i>Cancer Research</i> , 2014, 74, 2160-2170.	0.9	150
146	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2â€“Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3307-3329.	15.4	213
147	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 557-566.	2.5	59
148	Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 245-254.	2.5	41
149	Understanding how breast cancer patients use risk information from genomic tests. <i>Journal of Behavioral Medicine</i> , 2013, 36, 567-573.	2.2	13
150	The Management of Early-Stage and Metastatic Triple-Negative Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 737-749.	2.0	87
151	Phase II Trial of Bicalutamide in Patients with Androgen Receptorâ€“Positive, Estrogen Receptorâ€“Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5505-5512.	7.2	609
152	Dysregulation of the epigenome in triple-negative breast cancers: Basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. <i>Experimental and Molecular Pathology</i> , 2013, 95, 276-287.	2.3	60
153	Emerging therapies for triple-negative breast cancer. <i>Breast Cancer Management</i> , 2013, 2, 47-55.	0.2	1
154	Disparities in Breast Cancer Treatment and Outcomes: Biological, Social, and Health System Determinants and Opportunities for Research. <i>Oncologist</i> , 2013, 18, 986-993.	4.1	205
155	Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. <i>Oncologist</i> , 2013, 18, 123-133.	4.1	463
156	Engaging in Health Behaviors to Lower Risk for Breast Cancer Recurrence. <i>PLoS ONE</i> , 2013, 8, e53607.	2.5	33
157	Neoadjuvant Trials of Human Epidermal Growth Factor Receptor 2 Targeting: How Many Drugs Do We Need?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1909-1911.	15.4	4
158	Phase I Study and Biomarker Analysis of Lapatinib and Concurrent Radiation for Locally Advanced Breast Cancer. <i>Oncologist</i> , 2012, 17, 1496-1503.	4.1	13
159	TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2615-2623.	15.4	424
160	Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 35-43.	2.5	94
161	HER2â€“a good addiction. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 196-197.	27.6	16
162	Defining the expressed breast cancer kinome. <i>Cell Research</i> , 2012, 22, 620-623.	12.2	23

#	ARTICLE	IF	CITATIONS
163	CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 401-410.	2.5	81
164	The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1189-1196.	2.4	17
165	Improving communication of breast cancer recurrence risk. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 553-561.	2.5	65
166	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1057-1065.	2.5	185
167	Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 1508-1516.	2.0	407
168	Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3232-3239.	15.4	173
169	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor- $\alpha$ -negative breast cancer. <i>Nature Genetics</i> , 2011, 43, 1210-1214.	20.4	284
170	PARP and Cancer $\alpha$ ” If It’s Broke, Don’t Fix It. <i>New England Journal of Medicine</i> , 2011, 364, 277-279.	30.1	54
171	Clinical trials in triple negative breast cancer. <i>Breast Disease</i> , 2011, 32, 123-136.	0.8	29
172	Impact of Breast Cancer Molecular Subtypes on Locoregional Recurrence in Patients Treated with Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 2851-2857.	2.0	87
173	Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. <i>BMC Medical Genomics</i> , 2011, 4, 3.	1.5	147
174	The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. <i>Cancer</i> , 2011, 117, 1602-1611.	4.1	126
175	Directed Therapy of Subtypes of Triple-Negative Breast Cancer. <i>Oncologist</i> , 2011, 16, 71-78.	4.1	150
176	Breast Carcinomas Arising at a Young Age: Unique Biology or a Surrogate for Aggressive Intrinsic Subtypes?. <i>Journal of Clinical Oncology</i> , 2011, 29, e18-e20.	15.4	202
177	Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 465-470.	2.6	30
178	Women’s experiences with genomic testing for breast cancer recurrence risk. <i>Cancer</i> , 2010, 116, 1992-2000.	4.1	48
179	Altered-Function p53 Missense Mutations Identified in Breast Cancers Can Have Subtle Effects on Transactivation. <i>Molecular Cancer Research</i> , 2010, 8, 701-716.	3.5	59
180	Poly(ADP-Ribose) Polymerase Inhibition: $\alpha$ ”Targeted $\alpha$ ”Therapy for Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 4702-4710.	7.2	150

#	ARTICLE	IF	CITATIONS
181	Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study. <i>Clinical Cancer Research</i> , 2010, 16, 6100-6110.	7.2	365
182	Targeted Chemotherapy? Platinum in <i>BRCA1</i> -Dysfunctional Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 361-363.	15.4	34
183	Directed Therapy of Subtypes of Triple-Negative Breast Cancer. <i>Oncologist</i> , 2010, 15, 49-56.	4.1	44
184	Through a Glass Darkly: Advances in Understanding Breast Cancer Biology, 2000â€“2010. <i>Clinical Breast Cancer</i> , 2010, 10, 188-195.	2.6	40
185	Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptorâ€“Positive, Aromatase Inhibitorâ€“Resistant Advanced Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 774.	7.0	256
186	Breast Cancer Molecular Subtypes in Patients With Locally Advanced Disease: Impact on Prognosis, Patterns of Recurrence, and Response to Therapy. <i>Seminars in Radiation Oncology</i> , 2009, 19, 204-210.	2.3	105
187	A compact VEGF signature associated with distant metastases and poor outcomes. <i>BMC Medicine</i> , 2009, 7, 9.	5.7	165
188	Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial. <i>Journal of the American College of Surgeons</i> , 2009, 208, 906-914.	0.5	77
189	When genomic and standard test results diverge: implications for breast cancer patientsâ€™ preference for chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 25-29.	2.5	21
190	Reporting of race and ethnicity in breast cancer research: room for improvement. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 511-517.	2.5	18
191	CYP2D6 and tamoxifen: DNA matters in breast cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 576-586.	28.8	290
192	Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, S73-S81.	2.6	559
193	A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 99-107.	2.4	22
194	Polymorphisms in drug metabolism genes, smoking, and <i>p53</i> mutations in breast cancer. <i>Molecular Carcinogenesis</i> , 2008, 47, 88-99.	2.9	23
195	Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer. <i>Cancer Investigation</i> , 2008, 26, 1-10.	1.3	174
196	What is triple-negative breast cancer?. <i>European Journal of Cancer</i> , 2008, 44, 2799-2805.	2.9	279
197	Triple-Negative Breast Cancer: Risk Factors to Potential Targets. <i>Clinical Cancer Research</i> , 2008, 14, 8010-8018.	7.2	381
198	Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 191-194.	2.6	1

#	ARTICLE	IF	CITATIONS
199	Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 806-813.	15.4	69
200	Guidelines for the Initial Management of Metastatic Brain Tumors: Role of Surgery, Radiosurgery, and Radiation Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 505-514.	10.4	59
201	Gene-expression analysis and the basal-like breast cancer subtype. <i>Future Oncology</i> , 2007, 3, 55-63.	2.4	32
202	Women's Interest in Gene Expression Analysis for Breast Cancer Recurrence Risk. <i>Journal of Clinical Oncology</i> , 2007, 25, 4628-4634.	15.4	42
203	Retention and Use of Breast Cancer Recurrence Risk Information from Genomic Tests: The Role of Health Literacy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 249-255.	1.9	78
204	Gene expression profiling in breast cancer. <i>Current Opinion in Oncology</i> , 2007, 19, 547-551.	2.5	46
205	Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. <i>Breast Cancer Research</i> , 2007, 9, 110.	5.1	18
206	EGFR associated expression profiles vary with breast tumor subtype. <i>BMC Genomics</i> , 2007, 8, 258.	2.9	236
207	Molecular profiling in breast cancer. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2007, 8, 185-198.	5.8	36
208	Response and Cardiac Toxicity of Trastuzumab Given in Conjunction with Weekly Paclitaxel After Doxorubicin/Cyclophosphamide. <i>Clinical Breast Cancer</i> , 2006, 7, 237-243.	2.6	38
209	Axillary lymph node count is lower after neoadjuvant chemotherapy. <i>American Journal of Surgery</i> , 2006, 191, 827-829.	1.7	67
210	Clonal evolution of lymphoblastoid cell lines. <i>Laboratory Investigation</i> , 2006, 86, 1193-1200.	3.9	31
211	Size of Residual Lymph Node Metastasis After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients Is Prognostic. <i>Annals of Surgical Oncology</i> , 2006, 13, 685-691.	2.0	69
212	The molecular portraits of breast tumors are conserved across microarray platforms. <i>BMC Genomics</i> , 2006, 7, 96.	2.9	1,185
213	Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2492.	7.0	3,185
214	Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk. <i>Carcinogenesis</i> , 2006, 27, 2519-2527.	2.8	14
215	Estrogen-Regulated Genes Predict Survival in Hormone Receptor-Positive Breast Cancers. <i>Journal of Clinical Oncology</i> , 2006, 24, 1656-1664.	15.4	303
216	Current Treatment Paradigms for the Management of Patients with Brain Metastases. <i>Neurosurgery</i> , 2005, 57, S4-66-S4-77.	1.3	77

#	ARTICLE	IF	CITATIONS
217	American Joint Committee on Cancer Tumorâ€“Nodeâ€“Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1137-1142.	6.4	188
218	Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. <i>American Journal of Surgery</i> , 2005, 190, 371-375.	1.7	35
219	Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 777-785.	4.4	31
220	High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. <i>American Journal of Surgery</i> , 2004, 188, 386-389.	1.7	21
221	Long-Term Outcome of Neoadjuvant Therapy for Locally Advanced Breast Carcinoma. <i>Annals of Surgery</i> , 2002, 236, 295-303.	4.5	119
222	Clinical Significance of Micrometastatic Disease in the Era of Sentinel Node. <i>Breast Disease</i> , 2001, 12, 57-67.	0.8	1
223	Telomerase Activity and Prognosis in Primary Breast Cancers. <i>Journal of Clinical Oncology</i> , 1999, 17, 3075-3081.	15.4	52
224	Tuberculin skin test reactivity, anergy, and HIV infection in hospitalized patients. <i>American Journal of Medicine</i> , 1996, 100, 186-192.	1.4	28
225	Treatment of melanoma metastases in the brain. <i>Journal of Surgical Oncology</i> , 1996, 12, 429-435.	1.3	37
226	Quantifying the effect of ischemia on epiphyseal growth in an extremity replant model. <i>Journal of Hand Surgery</i> , 1990, 15, 625-630.	1.7	18
227	Oxygen Radical Scavengers Improve Vascular Patency and Bone-Muscle Cell Survival in an Ischemic Extremity Replant Model. <i>Plastic and Reconstructive Surgery</i> , 1989, 84, 117-123.	1.6	24
228	Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. <i>Nature Cancer</i> , 0, , .	12.3	16
229	Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptorâ€“Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. <i>JCO Oncology Practice</i> , 0, , .	2.8	1
230	Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial). <i>JCO Oncology Practice</i> , 0, , .	2.8	0